The thiazide-sensitive NaCl cotransporter (NCC) plays a key role in renal salt reabsorption and the determination of systemic BP, but the molecular mechanisms governing the regulation of NCC are not completely understood. Here, through pull-down experiments coupled to mass spectrometry, we found that ␥-adducin interacts with the NCC transporter. ␥-Adducin colocalized with NCC to the distal convoluted tubule.
Hypertension is a highly prevalent clinical condition and has been estimated to affect as many as 1.56 billion individuals in the year 2025. 1 Primary hypertension is a key contributor to cardiovascular complications. As such, hypertension has been estimated to account for a large fraction of strokes and ischemic heart disease on a global scale. 2 The National Vital Statistics Report lists heart disease as the primary cause of death, affecting more than 20 million people in the United States alone. 3 In addition, elevated BP is a leading cause in the development of chronic renal failure. 4 According to the Guytonian model, the kidney plays an essential role in chronic BP maintenance by adjusting blood volume in response to changes in systemic pressure. 5 Such modifications are achieved in part by amending the urinary excretion of NaCl.
The Joint National Committee for the detection, evaluation, and treatment of high BP recommends thiazides as the first line treatment of uncomplicated stage I hypertension. 6 Thiazides act by blocking NaCl reabsorption in the distal convoluted tubule (DCT), which reclaims 5 to 10% of Na ϩ from the renal ultrafiltrate. 7 It is therefore not surprising that disorders disturbing transport processes in this segment affect the renal reabsorptive capacity for NaCl and thereby influence systemic BP. The thiazide-sensitive NaCl transporter (NCC) is responsible for the majority of inward Na ϩ transport in the DCT. In line with this, renal NaCl transport and systemic BP can be changed in Gitelman patients 8, 9 and patients with pseudohypoaldosteronism type II. 10, 11 A better understanding of the regulation of NaCl transport by NCC may ultimately increase our understanding of how BP is maintained and the etiology of underlying primary hypertension. During the last decade, research within this field has greatly expanded our knowledge about how NaCl transport via NCC is controlled. The cotransporter contains several phosphorylation sites in its N-terminal domain, a feature that is well conserved among several members of the SLC12 family. [12] [13] [14] [15] Phosphorylation of these residues is critically important for the activation of NCC in response to chloride (Cl Ϫ ) depletion. 12 Serine/threonine kinases of the STE20 family (such as the Ste20-related proline-alanine-rich kinase (SPAK) and oxidative stress response 1 (OSR1)) as well as the With No Lysine (WNK) kinase family have been shown to play an important role in modulating the phosphorylation state of NCC. 16 -19 Genetically modified mice strains largely support these observations and solidify the important role of NCC regulation in BP maintenance. 20 -25 The aim of this study was to identify novel interactors of NCC that could be involved in modulating its function. Because the N-terminal domain has been shown to play an important role in activation of the transporter, pull-down experiments were performed with this domain of NCC in mouse kidney lysates and subsequently coupled with mass spectrometry. This study describes the identification of ␥-adducin as a novel auxiliary factor interacting with NCC. Adducins were originally identified as heteromeric cytoskeletal proteins implicated in the binding of spectrin to actin. 26 ␥-Adducin was selected as an interesting candidate on the basis of the previous involvement of this protein family in primary hypertension in both humans and rats. [27] [28] [29] Here, we delineated the molecular basis by which ␥-adducin stimulates the activity of NCC.
RESULTS
To investigate potential binding partners of the N-terminal domain of NCC, pull-down experiments were performed to screen mouse kidney lysates. The glutathione S-transferase (GST)-coupled N-terminal domain of NCC was used as bait, and the associated proteins were identified by mass spectrometry. The selection of the proteins of interest was based on localization to the distal nephron within the kidney and whether they had previously been involved in hypertension. ␥-Adducin was an interesting candidate that was chosen for further evaluation. The interaction was confirmed by pulldown experiments in human embryonic kidney (HEK) 293 cells transiently transfected with GST-conjugated terminal domains of NCC and hemagglutinin (HA)-tagged ␥-adducin. The resulting cell lysates were incubated with glutathione-coupled Sepharose beads to precipitate GST-bound complexes. Binding was seen by ␥-adducin toward the N-terminal domain of NCC ( Figure 1A) .
␥-Adducin has previously been localized to the renal distal tubules, 30 whereas actual colocalization with NCC in the DCT was never reported. Immunofluorescence labeling showed that ␥-adducin localizes to the NCC-expressing DCT tubules ( Figure 1B) . Here, ␥-adducin localized to cytoplasmic and (baso)-lateral domains of the cell. ␥-Adducin was not restricted to the DCT, because expression was also found in the proximal tubule and thick ascending limb as reported previously. 31 To evaluate whether the abundance of ␥-adducin is enriched in the DCT in comparison with other tubules in the renal cortex, DCT fragments were isolated from mice expressing enhanced green fluorescence protein (eGFP) after the parvalbumin promoter. 32 The restricted renal expression of this protein to the DCT allowed fluorescence-based sorting of the segment using a complex object parametric analyzer and sorter (COPAS). 33 In line with the more ubiquitous expression pattern of the protein as observed by immunohistochemistry, the relative enrichment of ␥-adducin mRNA in the DCT remained unaltered, whereas that for NCC was markedly enriched ( Figure 1C ).
To estimate the functional effect of ␥-adducin on the transport capacity of NCC, 22 Na ϩ uptake studies were performed using the Xenopus laevis oocyte system. Oocytes injected with cRNA encoding NCC showed a significant thiazide-sensitive 22 
Na
ϩ uptake compared with water-injected oocytes. Coinjection with increasing amounts of ␥-adducin cRNA stimulated NCC activity in a dose-dependent manner ( Figure 1D ). In addition, no difference in the expression level of HA-NCC could be detected between oocytes injected without or with increasing concentrations of HA-tagged ␥-adducin in the presence of HA-NCC. A dose-dependent increase was observed in the abundance of the HA-tagged ␥-adducin.
To evaluate whether ␥-adducin plays a role in maintaining basal NCC-dependent 22 
ϩ transport in the oocyte, small interference RNA (siRNA) against endogenous X. laevis ␥-adducin was injected in oocytes preinjected with NCC. When siRNA against ␥-adducin was injected, a significant decrease in thiazide-sensitive 22 
ϩ uptake was observed (Supplemental Figure 1A) . Because the related family member ␣-adducin does not affect NCC-dependent transport (Supplemental Figure 1B) , the oocytes were injected with siRNA against ␣-adducin as a negative control. Injection of ␣-adducin siRNA did not significantly affect the activity of NCC.
To investigate whether ␥-adducin affects NCC activity via the same signaling cascade as WNK4, the effect of WNK4 on ␥-adducin-stimulated Na ϩ transport was evaluated. WNK4 has been shown to reduce NCC activity by directing the protein to the lysosomal compartment. 34, 35 In line with this, WNK4 was able to inhibit NCC-dependent 22 
ϩ uptake (Figure 2A ). Importantly, the stimulatory effect of ␥-adducin was also ob-BASIC RESEARCH www.jasn.org served in the presence of WNK4 (Figure 2A) . Moreover, injections of increasing concentrations of ␥-adducin reverted the inhibitory effect of WNK4 on NCC-mediated 22 Na ϩ uptake ( Figure 2B) . Furthermore, the effect of ␥-adducin abrogated the WNK4-dependent reduction in NCC activity, because the stimulatory effect of ␥-adducin was still present when increasing amounts of WNK4 cRNA were injected ( Figure 2C ).
The stimulatory effect of ␥-adducin on NCC may be explained by increased trafficking of the transporter to the plasma membrane or by changes in the intrinsic activity of the transporter. To evaluate whether the membrane abundance of NCC increases in the presence of ␥-adducin, cell surface expression of eGFP-NCC was determined by confocal laser scanning microscopy. The intensity of the eGFP signal at the plasma membrane as well as the 22 
ϩ uptake rates correlated dose-dependently with the amount of injected eGFP-NCC cRNA ( Figure 3, A and B) . Thus, this method was used to determine semiquantitatively the presence of NCC at the plasma membrane. Coinjection of ␥-adducin significantly increased eGFP-NCC-dependent 22 
ϩ uptake, whereas the auxiliary protein ␥-adducin did not significantly affect the plasma membrane expression of eGFP-NCC ( Figure 3, C and D) .
To delineate whether ␥-adducin affects NCC function by its interaction with the N terminus of NCC, competition assays were performed in which NCC and ␥-adducin were coinjected together with increasing amounts of the N terminus of NCC. During these conditions, injection of the NCC N terminus abolished the stimulatory effect of ␥-adducin on NCC activity ( Figure 4A ).
The binding site of ␥-adducin in the N terminus of NCC was subsequently mapped by pull-down analysis. For determination of the binding site, a series of fragments from the N-terminal domain of NCC were generated as depicted in Figure 4B , with residues 1 to 135 representing the full-length N-tail. All of the N-terminal fragments were fused to GST to allow precipitation using , and Ser 73 in human NCC), which previously have been shown necessary for activation of the protein in response to Cl Ϫ depletion, 12 the role of ␥-adducin on the phosphorylation of NCC was evaluated. ␥-Adducin was coinjected with triple phosphorylation site NCC mutants (converted to alanines (A) or aspartates (D) to mimic either the constitutively inactive or active sites, respectively), and 22 Na ϩ uptakes were performed. The stimulatory effect of ␥-adducin on NCC-mediated Na ϩ transport was lost when the three phosphorylation sites were converted into constitutively active sites (D) ( Figure 4E ), suggesting an important role of ␥-adducin in modulating the phosphorylation of NCC. Similarly, when the N-terminal phosphorylation sites were converted to inactive phosphorylation sites (A), NCC-dependent 22 Na ϩ transport dropped markedly in line with previously published data ( Figure 4E ). 12 Also in this experimental setting, when the phosphorylation sites were made constitutively inactive, ␥-adducin had no effect on NCC-mediated 22 Na ϩ transport. These data suggest that the stimulatory effect of ␥-adducin is critically dependent on the phosphorylation sites in the N-terminal domain of NCC. To further elucidate the relationship between ␥-adducin and NCC, pull-down experiments were performed to determine whether binding of ␥-adducin to the N-tail of NCC was dependent on the phosphorylation status of this domain. Thus, GST pull-downs were performed using the N terminus of NCC as well as the N-terminal constitutively inactive or active phosphorylation forms ( Figure 4F ). Binding of ␥-adducin was found to the N terminus of wild-type NCC and the constitutively inactive form, whereas no binding was observed to the constitutive active phosphorylation form of NCC.
DISCUSSION
NCC is of crucial importance for the reabsorption of NaCl by the kidney, thus influencing arterial pressure. Here, we report the identification of ␥-adducin, a novel auxiliary protein interacting with the N-terminal domain of NCC. Our study is the first to delineate the stimulatory action of ␥-adducin on the thiazidesensitive NaCl cotransporter and highlights that the effect of ␥-adducin is critically dependent on the phosphorylation status of NCC. These observations are based on the following data: (1) the identified protein ␥-adducin binds strongly to the N-terminal domain of NCC and markedly stimulates the activity of the transporter; (2) the stimulatory actions of ␥-adducin occur in the regulatory cascade before the WNK4-dependent lysosomal shuttling of NCC; (3) competition with increasing amounts of the N-terminal part of NCC completely reverts the stimulatory action of ␥-adducin on thiazide-sensitive 22 Na ϩ transport; (4) the ␥-adducin-binding site is mapped to the part of the N-ter- 22 Na ؉ uptakes in oocytes coinjected with 5 ng of NCC cRNA, 10 ng of WNK4 cRNA, and increasing amounts of ␥-adducin cRNA (from 20 to 40 ng) (n ϭ 3). (C) WNK4 did not revert the stimulatory effect of ␥-adducin. 22 Na ؉ uptakes in oocytes coinjected with 5 ng of NCC cRNA, 10 ng of ␥-adducin cRNA, and increasing amounts of WNK4 cRNA (from 20 to 60 ng) (n ϭ 3). The closed bars denote the presence of 0.1 mM thiazide. *P Ͻ 0.05 is statistically significant from NCC-injected oocytes. #P Ͻ 0.05 is statistically significant from the group coinjected with WNK4 and NCC.
BASIC RESEARCH www.jasn.org minal domain of NCC that encompasses three phosphorylation sites that previously have been shown to affect the activity of the cotransporter; (5) NCC forms lacking phosphorylatable sites in the N terminus do not exhibit increased 22 Na ϩ transport rates when coinjected with ␥-adducin; and (6) ␥-adducin dissociates from NCC when the phospho-residues are converted to aspartates, mimicking a constitutively active phosphorylated state.
␥-Adducin was originally cloned from rat kidney. 36 The protein exhibits homology with the previously identified ␣-and ␤-adducin family members. Adducins are heteromeric membrane skeletal proteins originally implicated in spectrin-actin binding. 26 The adducins form heteromeric proteins composed of either ␣-and ␤-subunits or ␣-and ␥-subunits. Because the ␤-subunit has a restricted expression and is primarily found in brain and hemopeotic tissues, it has been suggested that the ␣-and ␥-subunits function as heteromers in tissues where the ␤-subunit is absent. 36 It is interesting to note that although ␥-adducin localizes to the DCT with NCC, ␣-adducin, which is also expressed in the kidney, seems absent from the distal tubules, although expression of both reappears in the collecting duct. 31 This may suggest that ␥-adducin has a unique function in DCT, where it could function as a homomer. In line with this is our observation that ␣-adducin fails to stimulate the activity of NCC in the oocyte system. The adducin gene family has previously been implicated in arterial hypertension. A G460W polymorphism in the ␣-adducin gene showed linkage to primary hypertension in certain patient groups. 27 One intronic single nucleotide polymorphism has currently been described in the ␥-adducin gene (A/G; rs3731566), which correlates with peripheral and central pulse pressures (because of increases in systolic pressure), changes in the urinary Na ϩ /K ϩ ratio, and urinary aldosterone excretion, but only in individuals that also harbor the G460W polymorphism in ␣-adducin. 37 These observations suggest that ␥-adducin can affect BP; however, to be visible clinically, arterial pressure needs to be perturbed by the G460W polymorphism in ␣-adducin.
␥-Adducin is able to revert the inhibitory effect of WNK4 on NCC. Consequently, our observation implies that ␥-adducin protects against the inhibitory actions of WNK4, either by affecting processes occurring before lysosomal removal of the protein or by directly blocking the WNK4-dependent inhibitory action on NCC. Because no changes in the membrane localization of NCC were observed after coinjection of ␥-adducin, one may conclude that ␥-adducin controls processes preceding lysosomal shuttling of NCC. The functional effect of phosphorylation of the thiazide-sensitive NCC transporter has not been fully delineated. Previous studies have reported that when the N-terminal phosphorylation sites in NCC are converted to alanines mimicking inactive phosphorylation sites, the activity of the transporter is markedly decreased. This occurs even although the membrane abundance remains unaffected, suggesting that the intrinsic activity is inhibited. 12 Similarly, when the transporter is incubated at hypotonic low Cl Ϫ conditions, which noticeably increases its phosphorylation level, NCC increases its activity, again independent of trafficking to the oocyte membrane. 12 In line with this finding is the observation that the Thr 96 -and Thr 101 -phosphorylated form of the related family member, the rat furosemide-sensitive Na ϩ , K ϩ , 2Cl Ϫ cotransporter (NKCC2) (corresponding to Thr 55 and Thr 60 phospho-form of human NCC), is found exclusively at the membrane as evaluated by electron microscopy. 38 Similarly to NCC in oocytes, when the phosphorylation level of NKCC2 is increased by growth hormone, no change in trafficking of the transporter can be observed. 12, 38 Consequently, the ␥-adducin-stimulated NCC activity needs to be explained by an intrinsic change in transporter activity, because the amount of trans- Representative images of GFP fluorescence at the oocyte membrane after injection with increasing amounts of GFP-NCC cRNA as well as the group coinjected with 10 ng of ␥-adducin cRNA using confocal laser scanning microscopy. *P Ͻ 0.05 is statistically significant.
porters in the membrane remains unchanged. Such changes could ensue, for instance, if affinity constants for Na ϩ or Cl Ϫ shift, to such a degree that the maximal velocity is altered. Thus, the data obtained in our study as well as the previous literature strongly imply a link between the phosphorylation state and the intrinsic activity of the transporter.
We found that the effect of ␥-adducin is entirely dependent on the phosphorylation sites of NCC. The sequence of Figure 4 . Phosphorylation of the N terminus of NCC is essential for the stimulatory effect of ␥-adducin. (A) The ability of the NCC N-terminal domain to inhibit ␥-adducin-stimulated transport of the cotransporter as evaluated by 22 Na ؉ uptakes. The oocytes were coinjected with 5 ng of NCC cRNA, 10 ng of ␥-adducin cRNA, and increasing amounts of the N-terminal domain of NCC (from 2.5 to 10 ng) (n ϭ 3). *P Ͻ 0.05 is statistically significant from all other groups. (B) Schematic drawing representing the GST fusion proteins containing different portions of the N-terminal tail of NCC. These were generated to map the binding site of ␥-adducin to NCC. Black domains represent the N-terminal phosphorylation sites, whereas gray denotes the SPAK binding site. (C) GST pull-down assay in HEK293 cells. Deletion fragments of the NCC N-terminal domain (amino acids 1 to 135, 1 to 80, and 1 to 40) coupled to GST were generated to determine the HA-␥-adducin-binding site within the cotransporter. (D) GST pull-down assay repeated, but the N terminus was truncated from the opposite end (amino acids 1 to 135, 40 to 135, 80 to 135, and 112 to 135). Note that ␥-adducin binds only in the presence of the full-length terminus or the 1 to 80 fragment. (E) The effect of ␥-adducin requires phosphorylatable NCC sites. 22 Na BASIC RESEARCH www.jasn.org ␥-adducin does not suggest that the protein is a kinase. Furthermore, there is no experimental evidence showing that ␥-adducin or other members of the family possess kinase activity. The most likely explanation is that ␥-adducin associates with kinases involved in the phosphorylation of the transporter, thereby anchoring them to the dephosphorylated N terminus of the transporter. The STE20 family of kinases, comprising members such as SPAK and OSR1, has been shown to increase the phosphorylation state of NCC in vitro and in vivo. 16, 24 In addition, WNK1, via SPAK and OSR1, has previously been shown to be responsible for increasing the transport activity and phosphorylation level of NCC during hypotonic Cl Ϫ -depleted conditions. 16 Moreover, WNK4 plays an important role in stimulating the NCC phosphorylation via SPAK and OSR1 in response to angiotensin II-mediated receptor activation. 39 The phosphorylation state of NCC is also markedly enhanced by dietary NaCl restriction, an effect that appears aldosterone-dependent and is lost in transgenic animals with a pseudohypoaldosteronism type II mutation in WNK4. 40 Consequently, phosphorylation of the N-terminal domain in NCC seems to be a common final pathway by which several stimuli converge to regulate the activity of the transporter. Here, we report that ␥-adducin may function as an important component in the phosphorylation cascade of NCC.
As can be observed from the immunohistochemical stainings, the ␥-adducin protein colocalizes with the NCC cotransporter to the DCT. ␥-Adducin is confined primarily to cytoplasmic domains oriented near the basolateral region of the cell, whereas NCC is found in apical domains of the cell. However, the adducins have previously been shown to play multiple roles within the cell, such as promoting cytoskeletal spectrin-actin binding, 26 and larger fractions of the ␥-adducin protein may be associated with those kind of structures, thus explaining the localization of the majority of protein. It is also unclear how the cytoskeleton is organized in the DCT after periodatelysine paraformaldehyde (PLP) fixation and freezing. Therefore, what is observed in the kidney section may not exactly mirror the subcellular localization of this protein in the native DCT cell. In addition, ␥-adducin is a cytoplasmic protein that may show a gradient in its distribution, where the large majority of the protein is localized to cytoskeletal structures, compatible with its multiple functions within the cell. Thus, only a minor fraction could be present at the apical plasma membrane. In primary renal proximal tubule epithelial cells, ␥-adducin is found in basolateral domains of the cell, whereas protein kinase C-dependent phosphorylation of the protein induces its redistribution toward the cytoplasm. 30 The potential regulation of ␥-adducin in the DCT as well as its subcellular distribution deserves further scrutiny, particularly after activation of intracellular signaling cascades that has been shown to affect the phosphorylation of NCC.
On the basis of the data generated in our study, we postulate that ␥-adducin stimulates NCC activity by anchoring a kinase, likely SPAK or OSR1 to the dephosphorylated transporter. Subsequently, the kinase increases the phosphorylation level of NCC, thereby stimulating the activity of the transporter. After the kinase-mediated phosphorylation event, ␥-adducin dissociates from NCC and may also facilitate the release of the associated kinase. Dephosphorylation of the transporter reduces the activity of NCC to its basal state. However, this event also allows for the binding of ␥-adducin to the N terminus again, and the cycle can be repeated. Thus, these speculations infer a dynamic model in which ␥-adducin binding and dissociation to NCC is directly correlated with the dephosphorylation and phosphorylation of the transporter, respectively.
In this study, the influence of ␥-adducin on NCC-dependent NaCl transport was evaluated using the X. laevis oocyte expression system. This in vitro system provides a powerful approach to directly study NCC function at the cellular and molecular level. In general, the results obtained in the oocyte expression system pertaining to the function and regulation of NCC mirror quite accurately those reported in vivo. 21, 24, 41 Despite the substantial success of the oocyte expression system, there are several limitations that should be noted. Obviously, the oocyte system represents a simplification of the in vivo situation and does not adequately reflect the complexity of the DCT cell, much less the kidney. In addition, several cofactors that may be necessary for the appropriate regulation of NCC could be absent from the oocyte. Thus, by recognizing these limitations in relation to the data obtained in this study, we can only extrapolate that the effect of ␥-adducin on NCC function is likely to occur in vivo. However, further studies in appropriate animal models are needed to definitively support this conclusion.
In summary, we identified ␥-adducin as a regulator of NCC in oocytes and showed that the stimulatory action of ␥-adducin is intimately linked with the N-terminal phosphorylation sites in the cotransporter. On the basis of our data, ␥-adducin may contribute importantly to the regulation of NCC and hence BP maintenance. Our findings will aid in the understanding of the complex cascade regulating NCC activity. Importantly, the observations made in our study may help elucidate the molecular events underlying the formation of primary hypertension.
CONCISE METHODS

Constructs
HA-tagged human NCC in pT7Ts has been previously described. 42 The human ␥-adducin clone was obtained from Imclone Systems (New York, NY), subcloned into a pCI-NEO-IRES-GFP vector, and further subcloned into pT7Ts. GST-conjugated N-and C-terminal fragments of NCC were subcloned by PCR to pGEX-6p-2 for Escherichia Coli protein production and further subcloned into pEBG vectors for expression of GST-fused proteins in HEK293 cells. GST-fused proteins containing different portions of the N-terminal domain of NCC were constructed according to the schematic drawing in Figure 4B . These constructs inserted in pEBG vectors were generated either by PCR subcloning or truncated by stop codons using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA). In addition, the N-terminal domain of NCC (amino acids 1 to 135) for the competition assay was generated by insertion of a stop codon by site-directed mutagenesis in the full-length NCC in pT7Ts. The triple phospho sites (Thr 55 , Thr 60 , and Ser 73 ) in NCC mimicking constitutively inactive (converted to alanines) or active (converted to aspartates) phosphoproteins were generated by site-directed mutagenesis in pT7Ts vectors. Similarly, the N termini with modified phosphorylation sites were further subcloned by PCR into pEBG for GST pull-down analysis. A Myc tag was inserted in front of WNK4 by subcloning, and the complete insert was placed into a pT7Ts vector using the gateway system (Invitrogen, Breda, The Netherlands). For generation of eGFP-NCC in pT7Ts, human NCC was subcloned by PCR from human NCC pT7Ts and constructed behind eGFP in a pCB7 vector. The complete insert was thereafter subcloned into pT7Ts. Human ␣-adducin (Imclone Systems) was subcloned into a pT7Ts vector. All of the inserts were verified by direct sequencing.
GST Pull-down and Mass Spectrometry
The intracellular N-and C-terminal domains of NCC coupled to GST were produced in E. Coli BL21 cells. The bacteria were lysed, and the GST-NCC terminal fusion domains were purified on glutathioneSepharose 4B beads (Amersham Pharmacia Biotech). C57BL/6 mice were killed under 1.5% vol/vol isofluorane anesthesia (Nicholas Piramal Limited, London, UK), and the kidneys were homogenized in lysis buffer (20 mM Tris/HCl, 140 mM NaCl, 1 mM CaCl 2 ,0.2% (vol/ vol) Triton X-100, 0.2% (vol/vol) NP-40, pH 7.4) containing protease inhibitors (0.10 mg/ml leupeptin, 0.05 mg/ml pepstatin-A, 1 mM phenylmethylsulfonyl fluoride, and 5 mg/ml aprotinin). The precipitated GST-terminal proteins were incubated overnight at 4°C with mouse kidney lysates. After extensive washing, the precipitates were placed on a SDS-PAGE gel and analyzed by the Nijmegen Proteomics Facility (Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, http://www.proteomicsnijmegen.nl/). Proteins were in-gel digested with trypsin. After extraction from the gel, the peptides were analyzed using nano-flow liquid chromatography coupled to a linear ion trap Fourier-transform mass spectrometer (LTQ FT; Thermo Fisher Scientific). Peptide and protein identifications were extracted from the data by means of the search program Mascot using the NCBI database 20080103 containing Mus musculus taxonomy with the addition of known contaminant proteins such as trypsin and human keratins. Precipitation of GST-coupled fusion domains of NCC with HA-tagged ␥-adducin in HEK293 cells was done as described in detail previously. 43 
COPAS Sorting and Semiquantitative Real-Time PCR Analysis
Transgene mice expressing eGFP after the parvalbumin promoter have been described previously. 32 The animals were anesthetized by an intraperitoneal injection of Hellabrunn mixture (ketamine, 0.05 mg/g of body weight; and xylazine, 0.02 mg/g of body weight) and perfused transcardially with digestion solution ( Nijmegen approved all of the experimental procedures. The kidney cortex was finely minced and incubated in digestion solution for 22 minutes at 37°C, subsequently sieved through a series of meshes, and finally collected on a 40-m filter. Fluorescently labeled DCT tubules were isolated from transgenic animals, using a COPAS sorter (Union Biometrica, Somerville, MA) as described in detail previously. 33 The GFP-positive fraction consists of DCT fragments. The remainder was saved and denoted whole kidney tubules. Tubule RNA was extracted using TRIzol Total RNA Isolation Reagent (Life Technologies BRL, Breda, The Netherlands) and processed into cDNA. The cDNA was mixed with Power SYBR® green PCR Mastermix (Applied Biosystems, Foster City, CA) and exon overlapping primers against ␥-adducin (5Ј-CACATCCACACCCTTGCCAC-3Ј; 5Ј-CCTGGTAGTCATAG-TAGGCGAC-3Ј), NCC (5Ј-CTTCGGCCACTGGCATTCTG-3Ј; 5Ј-GATGGCAAGGTAGGAGATGG-3Ј), and the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (5Ј-AACAT-CAAATGGGGTGA-3Ј; 5Ј-GGTTCACACCCATCACAA-3Ј).
In Vitro cRNA Translation pT7Ts plasmid vectors were linearized by restriction digestion at the 3Ј-end of the insert. The plasmids were transcribed in vitro using the mMESSAGE mMACHINE® T7 Kit (Ambion, Austin, TX) to generate cRNA. The integrity of the product was confirmed on 1% (wt/vol) agarose, 37% (vol/vol) formaldehyde gels. RNA concentrations were determined spectrophotometrically at 260 nm. The cRNA aliquots were stored at Ϫ80°C.
Evaluation of NCC Function
All of the animal experiments described below received the approval from the animal ethics board of Radboud University Nijmegen. Isolation and 22 Na ϩ uptakes in oocytes were done as described previously, 44, 45 with minor modifications. Briefly, X. laevis oocytes were surgically collected after decapitation, manually separated, and incubated in collagenase A (1 mg/ml). Incubations were done in Ca 2ϩ -free ND96 solution (96 mM NaCl, 2 mM KCl, 1 mM MgCl 2 , and 5 mM HEPES/NaOH, pH 7.4, 50 mg/L gentamicin). The following day, stage V and VI oocytes were selected and injected with the appropriate cRNAs in a final volume of 50 nl/oocyte. The oocytes were subsequently incubated in Ca 2ϩ -containing ND96 including 1.8 mM CaCl 2 for 2 to 3 days at 16°C. 16 hours before the uptake, the oocytes were placed in Cl Ϫ -depleted medium (96 mM sodium isethionate, 2 mM potassium gluconate, 1.8 mM calcium gluconate, 1 mM Mg(NO 3 Ϫ ) 2 , 5 mM HEPES/NaOH, pH 7.4, 50 mg/dl gentamicin, approximately 200 mOsm). Before the uptake, the oocytes were preincubated in 1 mM ouabain, 0.1 mM amiloride, and 0.1 mM bumetanide in the presence or absence of 0.1 mM thiazide in Cl Ϫ -depleted medium. 22 Na ϩ uptake (1 Ci 22 Na ϩ /ml; Perkin Elmer) was done in K ϩ -free isotonic uptake buffer (40 mM NaCl, 56 mM N-methyl-D-BASIC RESEARCH www.jasn.org glucamine (NMDG)-Cl, 1.8 mM CaCl 2 , 1 mM MgCl 2 , 5 mM HEPES/ NaOH, pH 7.4) for 1 hour. The oocytes were washed five times at the end of the 22 Na ϩ incubation with ice-cold uptake medium, transferred to scintillation vials, and lysed in 10% (w/v) sodium dodecyl sulfate. Radioactivity was counted in a liquid scintillation counter.
Evaluation of Total Expression of NCC and ␥-Adducin in the Oocyte
HA-NCC was detected in total membrane isolates, whereas HA-␥-adducin was detected in the remaining cytosolic fraction. As described in detail previously, 42 membrane preparations and total lysates were prepared, blotted onto membranes, and detected using an enhanced chemiluminescence system (Pierce, Rockford, IL).
Quantification of eGFP-NCC in the Oocyte Membrane
The oocytes were injected with 1, 5, or 10 ng of eGFP-NCC cRNA as well as 10 ng of eGFP-NCC cRNA in the presence of 10 ng of ␥-adducin. cRNA. Images were acquired on an Olympus FV1000 laserscanning microscope (Center Valley, PA, USA) using a 20ϫ objective. Background subtraction and semiquantitative determination of eGFP-NCC abundance at the plasma membrane was done using Image J (National Institutes of Health, Bethesda, MD).
siRNA against X. laevis ␥-Adducin
To confirm endogenous expression of ␥-adducin in X. laevis oocytes, primers designed against ␥-adducin in Xenopus tropicalis were used to amplify a fragment by RT-PCR (TaKaRa Taq TM , Shiga, Japan) from oocyte cDNA. The fragment was extracted from the gel and sequenced. Sequence similarity was identical to the previously published mRNA of hypothetical protein LOC432146 from X. laevis. siRNA was designed using doublestranded oligo-probes against the following sequence of endogenous X. laevis ␥-adducin, 5Ј-AATGACCCCGGCTACATCCGC-3Ј. Double-stranded probes were also designed against X. laevis ␣-adducin 5Ј-AATGGTGATTCGAGTGTAG-3Ј, on the basis of the previously published sequence (NM_001087641). Oocytes were injected with 5 ng of HA-NCC siRNA as described above. siRNAs were injected 24 hours before the uptake.
Immunohistochemistry
Kidneys from C57BL/6 mice were immersion fixated in 1% (w/v) PLP fixative. 10-m cryosections were prepared and costained with anti-␥-adducin antibodies (1:25, rabbit, H-60; Santa Cruz Biotechnology, Santa Cruz, CA) and NCC (1:100, guinea pig; generously provided by Jan Loffing, Switzerland). The images were acquired on an Olympus FV1000 laser-scanning microscope (Center Valley, PA).
Statistical Analysis
All of the results obtained in oocytes were the averages of two to eight independent experiments, each containing a minimum of ten oocytes per group. Overall statistics between groups was determined by one-way ANOVA. In case of significance, multiple comparisons between groups were performed by Bonferroni post hoc tests. The values are presented as the means Ϯ SEM. P Ͻ 0.05 is considered statistically significant.
